There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
More than 120 speakers and 5,000 delegates are expected to attend
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
Arizona-based, leading medical devices company, Confluent Medical Technologies, will be establishing a pilot manufacturing facility in Hyderabad.
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
